Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1872]

ASCO 2023: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2023: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

CDK4/6 inhibitors added to first line show no greater benefit when compared to...

Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands

CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC ( Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands )

Prognostic value of HER2-low status in breast cancer: A systematic review and...

Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis ( Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy )

PHERGain trial ID's early breast cancer cases that benefit from dual HER2...

Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo ( Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain )

ASCO 2023: Breast cancer research highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2023: Breast cancer research highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Adding ribociclib to endocrine therapy shows an improvement in invasive disease...

Prof Dennis Slamon - UCLA, Los Angeles, USA

Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients ( Prof Dennis Slamon - UCLA, Los Angeles, USA )

Nine-weeks trastuzumab still effective compared with one year trastuzumab for...

Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer ( Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy )

Oncologic safety of breast conservation following NACT in women with locally...

Dr Sanjit Agrawal - Tata Medical Center, Kolkata, India

Oncologic safety of breast conservation following NACT in women with locally advanced breast cancer ( Dr Sanjit Agrawal - Tata Medical Center, Kolkata, India )

Tackling low-volumes of clinical trials in Africa

Prof Ifeoma Okoye - University of Nigeria, Nsukka, Nigeria

Tackling low-volumes of clinical trials in Africa ( Prof Ifeoma Okoye - University of Nigeria, Nsukka, Nigeria )

Low-cost detection and treatment strategies for breast cancer patients in LMICs

Dr Anupama Mane - Ruby Hall Clinic, Pune, India

Low-cost detection and treatment strategies for breast cancer patients in LMICs ( Dr Anupama Mane - Ruby Hall Clinic, Pune, India )

Choosing wisely in breast cancer

Dr Anupama Mane - Ruby Hall Clinic, Pune, India

Choosing wisely in breast cancer ( Dr Anupama Mane - Ruby Hall Clinic, Pune, India )

The HypoAfrica study and AC3T research partnerships at NLCC

Dr Adedayo Joseph - NSIA-LUTH Cancer Center, Lagos, Nigeria

The HypoAfrica study and AC3T research partnerships at NLCC ( Dr Adedayo Joseph - NSIA-LUTH Cancer Center, Lagos, Nigeria )

More from ecancer